<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Clin Croat</journal-id><journal-id journal-id-type="iso-abbrev">Acta Clin Croat</journal-id><journal-id journal-id-type="publisher-id">ACC</journal-id><journal-title-group><journal-title>Acta Clinica Croatica</journal-title></journal-title-group><issn pub-type="ppub">0353-9466</issn><issn pub-type="epub">1333-9451</issn><publisher><publisher-name>Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6629194</article-id><article-id pub-id-type="publisher-id">acc-58-139</article-id><article-id pub-id-type="doi">10.20471/acc.2019.58.01.18</article-id><article-categories><subj-group subj-group-type="heading"><subject>Reviews</subject></subj-group></article-categories><title-group><article-title>HEREDITARY ANGIOEDEMA DUE TO C1-INHIBITOR DEFICIENCY IN PEDIATRIC PATIENTS IN CROATIA &#x02013; FIRST NATIONAL STUDY, DIAGNOSTIC AND PROPHYLACTIC CHALLENGES</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Karad&#x0017e;a-Lapi&#x00107;</surname><given-names>Ljerka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bare&#x00161;i&#x00107;</surname><given-names>Marko</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vrsalovi&#x00107;</surname><given-names>Renata</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ivkovi&#x00107;-Jurekovi&#x00107;</surname><given-names>Irena</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sr&#x00161;en</surname><given-names>Sa&#x00161;a</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Prka&#x0010d;in</surname><given-names>Ingrid</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rijavec</surname><given-names>Matija</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cikojevi&#x00107;</surname><given-names>Dra&#x00161;ko</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><aff><target id="aff1" target-type="aff"><sup>1</sup></target>Department of Otorhinolaryngology, <institution>&#x00160;ibenik General Hospital</institution>, <addr-line>&#x00160;ibenik</addr-line>, <country>Croatia</country>; <target id="aff2" target-type="aff"><sup>2</sup></target>Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, <institution>Zagreb University Hospital Centre</institution>, <addr-line>Zagreb</addr-line>, <country>Croatia</country>; <target id="aff3" target-type="aff"><sup>3</sup></target>Department of Pediatrics, <institution>Sestre milosrdnice University Hospital Centre</institution>, <addr-line>Zagreb</addr-line>, <country>Croatia</country>; <target id="aff4" target-type="aff"><sup>4</sup></target>Zagreb Children&#x02019;s Hospital, <addr-line>Zagreb</addr-line>, <country>Croatia</country>; Pediatric Department, Faculty of Medicine, <institution>Josip Juraj Strossmayer University of Osijek</institution>, <addr-line>Osijek</addr-line>, <country>Croatia</country>; <target id="aff5" target-type="aff"><sup>5</sup></target>Department of Pediatrics, <institution>Split University Hospital Centre</institution>, <addr-line>Split</addr-line>, <country>Croatia</country>; <target id="aff6" target-type="aff"><sup>6</sup></target>Department of Internal Medicine, School of Medicine, University of Zagreb, <institution>Merkur University Hospital</institution>, <addr-line>Zagreb</addr-line>, <country>Croatia</country>; <target id="aff7" target-type="aff"><sup>7</sup></target>Golnik University Clinic of Pulmonary and Allergic Diseases, Golnik, <country>Slovenia</country>; <target id="aff8" target-type="aff"><sup>8</sup></target>Department of Otorhinolaryngology, <institution>Split University Hospital Centre</institution>, <addr-line>Split</addr-line>, <country>Croatia</country></aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: <italic>Ljerka Karad&#x0017e;a-Lapi&#x00107;, MD, PhD</italic>, &#x00160;ibenik General Hospital, Stjepana Radi&#x00107;a 84, HR-22000 &#x00160;ibenik, Croatia&#x02028;E-mail: <email xlink:href="ljerka.karadzalapic@gmail.com">ljerka.karadzalapic@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>3</month><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>3</month><year>2019</year></pub-date><volume>58</volume><issue>1</issue><fpage>139</fpage><lpage>146</lpage><history><date date-type="received"><day>21</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2018</year></date></history><permissions><copyright-year>2019</copyright-year><copyright-holder>Sestre Milosrdnice University Hospital</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license></permissions><abstract><title>SUMMARY</title><p>Hereditary angioedema (HAE) is a rare autosomal dominant disease with deficiency (type I) or dysfunction (type II) of C1 inhibitor, caused by mutations in the C1-INH gene, characterized by recurrent submucosal or subcutaneous edemas including skin swelling, abdominal pain and life-threatening episodes of upper airway obstruction. The aim of this study was to investigate healthcare experiences in children with HAE due to C1 inhibitor deficiency (C1-INH-HAE) in Croatia in order to estimate the number of affected children and to recommend management protocols for diagnosis, short-term prophylaxis and acute treatment. Patients were recruited during a 4-year period at five hospitals in Croatia. Complement testing was performed in patients with a positive family history. This pilot study revealed nine pediatric patients positive for C1-INH- HAE type I, aged 1-16 years, four of them asymptomatic. Before the age of one year, C1-INH levels may be lower than in adults; it is advisable to confirm C1-INH-HAE after the age of one year. Plasma-derived C1-INH is recommended as acute and short-term prophylactic treatment. Recombinant C1-INH and icatibant are licensed for the acute treatment of pediatric patients. In Croatia, HAE is still underdiagnosed in pediatric population.</p></abstract><kwd-group kwd-group-type="author"><title>Key words: </title><kwd>Hereditary angioedema types I and II &#x02013; diagnosis</kwd><kwd>Complement C1 inhibitor protein</kwd><kwd>Child</kwd><kwd>Croatia</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Hereditary angioedema (HAE) due to C1 inhibitor deficiency (C1-INH-HAE) is a rare autosomal dominant disease with deficiency (type I C1-INH-HAE) or dysfunction (type II C1-INH-HAE) of C1 inhibitor (C1-INH) due to mutations in the <italic>SERPING1</italic> gene (<xref rid="r1" ref-type="bibr"><italic>1</italic></xref>-<xref rid="r3" ref-type="bibr"><italic>3</italic></xref>). In some patients with a normal level of C1-INH, angioedema is related to mutation in coagulation factor XII gene (HAE-FXII), plasminogen (HAE-PLG) and angiopoetin-1 (HAE-ANGPT1), or the cause of angioedema remains unknown (U-HAE) (<xref rid="r2" ref-type="bibr"><italic>2</italic></xref>, <xref rid="r4" ref-type="bibr"><italic>4</italic></xref>). All types of the disease share the same clinical presentation due to unregulated generation of bradykinin causing leakage of plasma from postcapillary venules (<xref rid="r5" ref-type="bibr"><italic>5</italic></xref>-<xref rid="r7" ref-type="bibr"><italic>7</italic></xref>). Clinical events in the population with C1-INH-HAE are characterized by recurrent submucosal or subcutaneous edemas including skin swelling, abdominal pain and life-threatening episodes of upper airway obstruction. Attacks may occur at any age after birth but early onset of symptoms may predict a more severe course of the disease, which worsens in puberty (<xref rid="r8" ref-type="bibr"><italic>8</italic></xref>). The most common attack triggers include mechanical trauma, stress and infections (<xref rid="r9" ref-type="bibr"><italic>9</italic></xref>, <xref rid="r10" ref-type="bibr"><italic>10</italic></xref>). Also, dental-oral procedures, endoscopies or operations in general anesthesia with intubation can precipitate angioedema. If not treated, edema may persist for 1 to 5 days before resolving spontaneously (<xref rid="r11" ref-type="bibr"><italic>11</italic></xref>). The earliest and the most common swelling site in pediatric population is subcutaneous edema of the extremities. Upper airway edema is more severe in small children causing death by asphyxiation (<xref rid="r12" ref-type="bibr"><italic>12</italic></xref>, <xref rid="r13" ref-type="bibr"><italic>13</italic></xref>). Abdominal pain, vomiting and diarrhea, frequent in general pediatric population, are present in 80%-90% of HAE patients (<xref rid="r8" ref-type="bibr"><italic>8</italic></xref>). Edema can also affect genitalia, urinary bladder, muscles, joints, or can cause migraine or visual disturbances and headache (<xref rid="r8" ref-type="bibr"><italic>8</italic></xref>). The aim of this study was to investigate health care experiences in children with HAE in Croatia in order to estimate the number of affected children and to recommend management protocols for establishing HAE diagnosis, short- term prophylaxis before triggering procedures, and acute treatment of pediatric patients.</p></sec><sec sec-type="methods"><title>Patients and Methods</title><sec><title>Patients</title><p>The patients were recruited during a 4-year period (2012-2016) at five hospitals in Zagreb, &#x00160;ibenik and Split, Croatia. The diagnosis of C1-INH-HAE was established based on complement testing (complement C4 and C1 inhibitor antigenic levels) and characteristic clinical features such as upper airway and subcutaneous swelling or abdominal pain (<xref rid="r14" ref-type="bibr"><italic>14</italic></xref>). It was performed in nine patients from 18 families with confirmed C1-INH-HAE type I diagnosis. A questionnaire (Appendix), developed in line with the international consensus algorithm, was sent to each center, in order to explore patient experiences of the disease, including diagnosis and treatment (<xref rid="r2" ref-type="bibr"><italic>2</italic></xref>).</p><p>The study was approved by the participating hospital ethics committees and a parental written consent was granted.</p></sec><sec><title>Complement testing</title><p>Serum protein concentrations of C1 inhibitor (normal range: 0.20-0.35 g/L) and C4 (normal range: 0.16-0.31 g/L) were quantified using radial immunodiffusion (Siemens, Marburg, Germany). C1 inhibitor function was measured using an enzyme immunoassay (Quidel Corporation, California, USA) considering C1 inhibitor functional levels &#x02264;40% of normal value as decreased levels. All measurements were performed in accordance with the manufacturer&#x02019;s instructions.</p></sec><sec><title>Statistical analysis</title><p>No formal statistical hypothesis was tested. Statistical analysis was essentially descriptive (percentages).</p></sec></sec><sec sec-type="results"><title>Results</title><p>Our pilot study identified nine children with HAE with positive family history, aged 0-16 years. All of them tested positive for C1-INH-HAE type I; four of them were asymptomatic (patient 1, age 8; patient 3 age 15; patient 6, age 6; and patient 9, age 1) (<xref rid="t1" ref-type="table">Table 1</xref>). Detailed clinical data and complement measurements are outlined in <xref rid="t1" ref-type="table">Table 1</xref>. There were six female (F) and three male (M) patients. Age at onset of symptoms ranged from 1 to 15 years. The prime localization of the attacks was peripheral edema in 55% (5 patients = 3 F, ages 6, 8 and 16; and 2 M, ages 4 and 10), followed by facial swelling in 33% (3 patients = 2 F, ages 16 and 6; and 1 M, age 16), and laryngeal (1 M, age 16) and abdominal edema (1 F, age 6) in one patient (12%) each. Abdominal pain as a symptom of HAE was the prime localization of attacks in patient 8. In patient 2 with facial and neck edema, dental procedures precipitated facial and laryngeal attacks. Presentation of C1-INH-HAE in the upper airways was detected in patient 4. This study identified three adolescents.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Patient clinical and laboratory data</title></caption><table frame="hsides" rules="groups"><col width="4.86%" span="1"/><col width="6.2%" span="1"/><col width="6.2%" span="1"/><col width="10.35%" span="1"/><col width="8.27%" span="1"/><col width="8.27%" span="1"/><col width="8.28%" span="1"/><col width="8.27%" span="1"/><col width="8.27%" span="1"/><col width="10.35%" span="1"/><col width="10.34%" span="1"/><col width="10.34%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.25pt; border-bottom: solid 0.25pt" rowspan="1" colspan="1">Patient No.</th><th valign="middle" align="left" scope="col" style="border-left: solid 0.25pt; border-top: solid 0.50pt; border-right: solid 0.25pt; border-bottom: solid 0.25pt" rowspan="1" colspan="1">Gender (M/F)</th><th valign="middle" align="left" scope="col" style="border-left: solid 0.25pt; border-top: solid 0.50pt; border-right: solid 0.25pt; border-bottom: solid 0.25pt" rowspan="1" colspan="1">Age</th><th valign="middle" align="left" scope="col" style="border-left: solid 0.25pt; border-top: solid 0.50pt; border-right: solid 0.25pt; border-bottom: solid 0.25pt" rowspan="1" colspan="1">Age at onset of symptoms</th><th valign="middle" align="left" scope="col" style="border-left: solid 0.25pt; border-top: solid 0.50pt; border-right: solid 0.25pt; border-bottom: solid 0.25pt" rowspan="1" colspan="1">Skin edema</th><th valign="middle" align="left" scope="col" style="border-left: solid 0.25pt; border-top: solid 0.50pt; border-right: solid 0.25pt; border-bottom: solid 0.25pt" rowspan="1" colspan="1">Facial edema</th><th valign="middle" align="left" scope="col" style="border-left: solid 0.25pt; border-top: solid 0.50pt; border-right: solid 0.25pt; border-bottom: solid 0.25pt" rowspan="1" colspan="1">Abdominal edema</th><th valign="middle" align="left" scope="col" style="border-left: solid 0.25pt; border-top: solid 0.50pt; border-right: solid 0.25pt; border-bottom: solid 0.25pt" rowspan="1" colspan="1">Laryngeal edema</th><th valign="middle" align="left" scope="col" style="border-left: solid 0.25pt; border-top: solid 0.50pt; border-right: solid 0.25pt; border-bottom: solid 0.25pt" rowspan="1" colspan="1">Family history</th><th valign="middle" align="left" scope="col" style="border-left: solid 0.25pt; border-top: solid 0.50pt; border-right: solid 0.25pt; border-bottom: solid 0.25pt" rowspan="1" colspan="1">C4 (g/L)<break/>(normal range 0.16-0.31)</th><th valign="middle" align="left" scope="col" style="border-left: solid 0.25pt; border-top: solid 0.50pt; border-right: solid 0.25pt; border-bottom: solid 0.25pt" rowspan="1" colspan="1">C1-INH (g/L)<break/>(normal range 0.20-0.35)</th><th valign="middle" align="left" scope="col" style="border-left: solid 0.25pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.25pt" rowspan="1" colspan="1">C1-INH function, %, (decreased &#x02264;40%)</th></tr></thead><tbody><tr><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.25pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" scope="row" rowspan="1" colspan="1">1</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.25pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">F</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.25pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">8</td><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.25pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">Asympt</td><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.25pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1"/><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.25pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1"/><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.25pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1"/><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.25pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1"/><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.25pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.25pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.05</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.25pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.05</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.25pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">36</td></tr><tr><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" scope="row" rowspan="1" colspan="1">2</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">F</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">16</td><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">15</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.05</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">&#x0003c;0.05</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">30</td></tr><tr><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" scope="row" rowspan="1" colspan="1">3</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">F</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">15</td><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">Asympt</td><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1"/><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1"/><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1"/><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1"/><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.05</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.05</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">17</td></tr><tr><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" scope="row" rowspan="1" colspan="1">4</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">M</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">16</td><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">6</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.06</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.05</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">20</td></tr><tr><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" scope="row" rowspan="1" colspan="1">5</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">F</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">8</td><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">3</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.15</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.09</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">33</td></tr><tr><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" scope="row" rowspan="1" colspan="1">6</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">M</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">6</td><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">Asympt</td><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1"/><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1"/><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1"/><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1"/><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">&#x0003c;0.05</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.06</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">24</td></tr><tr><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" scope="row" rowspan="1" colspan="1">7</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">M</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">4</td><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">1</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.11</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.13</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">56</td></tr><tr><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" scope="row" rowspan="1" colspan="1">8</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">F</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">6</td><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">3</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.07</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">0.05</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" rowspan="1" colspan="1">33</td></tr><tr><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">9</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">F</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">1</td><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Asympt</td><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"/><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"/><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"/><td valign="middle" align="left" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"/><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x0003c;0.05</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.25pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">0.15</td><td valign="middle" align="center" style="border-left: solid 0.25pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">48</td></tr></tbody></table><table-wrap-foot><p>Asympt = asymptomatic; M = male; F = female; C1-INH = C1 inhibitor</p></table-wrap-foot></table-wrap><p>Plasma-derived C1-INH (pdC1-INH, human) was administered as acute treatment in the patient with laryngeal, facial and neck edema (20 IU <italic>per</italic> kg body weight by intravenous injection).</p><p>In this study, C1-INH-HAE was diagnosed before or immediately after symptom onset.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Using an estimated prevalence of 1:50 000 and national census statistics of 896 605 children aged 19 years or less in Croatia, approximately 18 children would be expected to have this disease (<xref rid="r15" ref-type="bibr"><italic>15</italic></xref>). In this study, we detected nine children with C1-INH-HAE type I from 18 families with positive family history; one of them (patient 4) was the first family member with established proper C1-INH-HAE diagnosis. HAE is a life-altering and chronic disease. This investigation emphasized the variety of clinical presentation of the disease and possible delay in reaching an accurate diagnosis due to that variety. C1-INH-HAE type I diagnosis is corroborated with low levels of serum protein concentrations of C1-INH and C4, and type II with low level of C4 and normal or above normal level of ineffective C1-INH. The diagnosis can be further supported by genetic testing. All neonates/infants with an affected C1-INH-HAE family member should be screened for C1-INH deficiency; genetic testing is indicated under the age of one year (<xref rid="r14" ref-type="bibr"><italic>14</italic></xref>). Genetic testing is also indicated for HAE-FXII, HAE-PLG and HAE-ANGPT1 while U-HAE diagnosis can be established with positive family history and typical clinical presentation.</p><p>Complement testing is available in clinical centres throughout Croatia, while genetic testing can be performed in collaboration with the University Clinic of Pulmonary and Allergic Diseases Golnik, Slovenia, in agreement with the Croatian Health Insurance Fund (<xref rid="r10" ref-type="bibr"><italic>10</italic></xref>).</p><p>Abdominal pain commonly occurs in the general pediatric population. Differential diagnosis can be difficult as abdominal pain is common in pediatric C1-INH-HAE population, as recorded in patient 8 (<xref rid="r14" ref-type="bibr"><italic>14</italic></xref>). HAE is often underdiagnosed or misdiagnosed as a cause of abdominal pain. During abdominal edema attack, HAE patients are usually observed as cases of gastroenterocolitis or acute abdomen, or may undergo unnecessary surgical procedures (<xref rid="r16" ref-type="bibr"><italic>16</italic></xref>). Ultrasound findings of abdominal fluid and bowel swelling can help differentiate patients with HAE (<xref rid="r17" ref-type="bibr"><italic>17</italic></xref>). C1-INH-HAE diagnosis should be early established and also considered in patients experiencing recurrent angioedema with poor response to epinephrine, glucocorticoids and antihistamines, since they are ineffective in C1-INH-HAE (<xref rid="r1" ref-type="bibr"><italic>1</italic></xref>, <xref rid="r18" ref-type="bibr"><italic>18</italic></xref>-<xref rid="r20" ref-type="bibr"><italic>20</italic></xref>). Some children may develop prodromal nonpruritic rash, erythema marginatum, but urticaria with itching at any age practically excludes HAE diagnosis (<xref rid="r8" ref-type="bibr"><italic>8</italic></xref>, <xref rid="r20" ref-type="bibr"><italic>20</italic></xref>).</p><sec><title>Puberty and oral hormonal contraceptives</title><p>Puberty can aggravate the symptoms of HAE, particularly in females, triggered by menstruation and ovulation (<xref rid="r9" ref-type="bibr"><italic>9</italic></xref>). Estrogen-containing medications for acne or oral contraceptives can precipitate attacks, so they are not recommended in patients with HAE (<xref rid="r14" ref-type="bibr"><italic>14</italic></xref>).</p></sec><sec><title>Medical procedures and HAE</title><p>Physicians can trigger an HAE attack with their procedures. Dental procedures can precipitate facial and laryngeal attacks, as it was the case in patient 2 with facial and neck edema (<xref rid="r13" ref-type="bibr"><italic>13</italic></xref>). Presentation of C1-INH-HAE in the upper airways, as in patient 4, may lead to asphyxiation, the time from symptom onset to asphyxiation varying from as little as 20 minutes to as long as 30 hours, making tracheotomy a lifesaving treatment (<xref rid="r13" ref-type="bibr"><italic>13</italic></xref>, <xref rid="r21" ref-type="bibr"><italic>21</italic></xref>). Education of patients, parents and child care workers about laryngeal symptoms that may lead to asphyxiation, such as hoarseness, lump in the throat or shortness of breath, is crucial. Endoscopy procedures or operations in general anesthesia with intubation that are common in pediatric population, such as adenotonsillectomy or appendectomy, might lead to laryngeal edema or painful abdominal edema. PdC1-INH is recommended as a short-term prophylactic treatment 1-2 hours before triggering procedures at a dose of 20 IU <italic>per</italic> kg body weight by intravenous injection (<xref rid="r14" ref-type="bibr"><italic>14</italic></xref>). If pdC1-INH is not available, attenuated oral androgen danazol 5 mg/kg/day or 10 mL/kg solvent detergent plasma (SDP) can be administered (<xref rid="r14" ref-type="bibr"><italic>14</italic></xref>). Prophylaxis with danazol should start 5 days before and be continued for 2 days postprocedure. Treatment with pdC1-INH and recombinant C1-INH (rhC1-INH) to replace the functionally or quantitatively deficient C1-INH in patients with HAE has been shown to be effective for treating acute edematous attacks at any site in children. PdC1-INH is licensed for children at any age in a dose of 20 IU <italic>per</italic> kg body weight and rhC1-INH (conestat alfa) or kallikrein inhibitor (ecallantide, only in the USA) for those older than 12 years (<xref rid="r14" ref-type="bibr"><italic>14</italic></xref>, <xref rid="r22" ref-type="bibr"><italic>22</italic></xref>). Conestat alfa should be administrered at a dose of 50 IU <italic>per</italic> kg body weight by intravenous injection (<xref rid="r15" ref-type="bibr"><italic>15</italic></xref>). Icatibant administered in children and adolescents subcutaneously based on body weight has been recently approved for children above the age of 2 years (<xref rid="r15" ref-type="bibr"><italic>15</italic></xref>). Icatibant is approved for self-administration, allowing patients/families to take control of their disease. SDP is indicated in emergency situations when licensed therapy is not available (or fresh frozen plasma (FFP) as a source of C1-INH). Individuals with HAE require lifelong therapy and evaluation of disease activity.</p><p>In conclusion, HAE is still underdiagnosed in pediatric population. This was the first survey of pediatric HAE in Croatia. According to these findings, we recommend comprehensive care, not only parental or medical, but also of all those included in the process of education in schools or kindergartens (<xref rid="r23" ref-type="bibr"><italic>23</italic></xref>). Also, identification card with individual treatment plan made by HAE specialist must be provided for each pediatric HAE patient. Dental-oral procedures, endoscopies or operations in general anesthesia can precipitate angioedema. Plasma-derived C1-INH is recommended as short-term prophylactic treatment before triggering procedures. Plasma-derived C1-INH, recombinant C1-INH (for children above 12 years) and icatibant (for children above 2 years) are licensed for the acute treatment of pediatric patients. Raising awareness about rare diseases among parents and physicians is essential for early and accurate establishment of the diagnosis, effective management of acute attacks and prior to triggering procedures in order to avoid unnecessary investigations and to prevent adverse events.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>The authors are grateful to Aleksandra Go&#x00161;ev, MD and Nenad Poljak, VD for great technical assistance.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuraw</surname><given-names>BL</given-names></name><name><surname>Christiansen</surname><given-names>SC</given-names></name></person-group>
<article-title>Pathophysiology of hereditary angioedema.</article-title>
<source>Am J Rhinol Allergy</source>. <year>2011</year>;<volume>25</volume>(<issue>6</issue>):<fpage>373</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.2500/ajra.2011.25.3661</pub-id><?supplied-pmid 22185738?><pub-id pub-id-type="pmid">22185738</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicardi</surname><given-names>M</given-names></name><name><surname>Aberer</surname><given-names>W</given-names></name><name><surname>Banerji</surname><given-names>A</given-names></name><name><surname>Bas</surname><given-names>M</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Bork</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group.</article-title>
<source>Allergy</source>. <year>2014</year>;<volume>69</volume>(<issue>5</issue>):<fpage>602</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1111/all.12380</pub-id><?supplied-pmid 24673465?><pub-id pub-id-type="pmid">24673465</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalm&#x000e1;r</surname><given-names>L</given-names></name><name><surname>Hegedus</surname><given-names>T</given-names></name><name><surname>Farkas</surname><given-names>H</given-names></name><name><surname>Nagy</surname><given-names>M</given-names></name><name><surname>Tordai</surname><given-names>A</given-names></name></person-group>
<article-title>HAEdb: a novel interactive, locus-specific mutation database for the C1 inhibitor gene.</article-title>
<source>Hum Mutat</source>. <year>2005</year>;<volume>25</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/humu.20112</pub-id><?supplied-pmid 15580551?><pub-id pub-id-type="pmid">15580551</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bj&#x000f6;rkqvist</surname><given-names>J</given-names></name><name><surname>de Maat</surname><given-names>S</given-names></name><name><surname>Lewandrowski</surname><given-names>U</given-names></name><name><surname>Di Gennaro</surname><given-names>A</given-names></name><name><surname>Oschatz</surname><given-names>C</given-names></name><name><surname>Schonig</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III.</article-title>
<source>J Clin Invest</source>. <year>2015</year>;<volume>125</volume>(<issue>8</issue>):<fpage>3132</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1172/JCI77139</pub-id><?supplied-pmid 26193639?><pub-id pub-id-type="pmid">26193639</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuraw</surname><given-names>BL</given-names></name><name><surname>Christiansen</surname><given-names>SC</given-names></name></person-group>
<article-title>HAE Pathophysiology and underlying mechanisms.</article-title>
<source>Clin Rev Allergy Immunol</source>. <year>2016</year>;<volume>51</volume>(<issue>2</issue>):<fpage>216</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1007/s12016-016-8561-8</pub-id><?supplied-pmid 27459852?><pub-id pub-id-type="pmid">27459852</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bj&#x000f6;rkqvist</surname><given-names>J</given-names></name><name><surname>Sala-Cunill</surname><given-names>A</given-names></name><name><surname>Renne</surname><given-names>T</given-names></name></person-group>
<article-title>Hereditary angioedema: a bradykinin-mediated swelling disorder.</article-title>
<source>Thromb Haemost</source>. <year>2013</year>;<volume>109</volume>(<issue>3</issue>):<fpage>368</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1160/TH12-08-0549</pub-id><?supplied-pmid 23306453?><pub-id pub-id-type="pmid">23306453</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>AP</given-names></name></person-group>
<article-title>Bradykinin and the pathogenesis of hereditary angioedema.</article-title>
<source>World Allergy Organ J</source>. <year>2011</year>;<volume>4</volume>(<issue>4</issue>):<fpage>73</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1097/WOX.0b013e318216b7b2</pub-id><?supplied-pmid 23282402?><pub-id pub-id-type="pmid">23282402</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Meng</surname><given-names>G</given-names></name><name><surname>Staubach</surname><given-names>P</given-names></name><name><surname>Hardt</surname><given-names>J</given-names></name></person-group>
<article-title>Hereditary angioedema: new findings concerning symptoms, affected organs, and course.</article-title>
<source>Am J Med</source>. <year>2006</year>;<volume>119</volume>(<issue>3</issue>):<fpage>267</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjmed.2005.09.064</pub-id><?supplied-pmid 16490473?><pub-id pub-id-type="pmid">16490473</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farkas</surname><given-names>H</given-names></name></person-group>
<article-title>Pediatric hereditary angioedema due to C1-inhibitor deficiency.</article-title>
<source>Allergy Asthma Clin Immunol</source>. <year>2010</year>;<volume>6</volume>(<issue>1</issue>):<fpage>18</fpage>. <pub-id pub-id-type="doi">10.1186/1710-1492-6-18</pub-id><?supplied-pmid 20667121?><pub-id pub-id-type="pmid">20667121</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rijavec</surname><given-names>M</given-names></name><name><surname>Korosec</surname><given-names>P</given-names></name><name><surname>Silar</surname><given-names>M</given-names></name><name><surname>Zidarn</surname><given-names>M</given-names></name><name><surname>Miljkovic</surname><given-names>J</given-names></name><name><surname>Kosnik</surname><given-names>M</given-names></name></person-group>
<article-title>Hereditary angioedema nationwide study in Slovenia reveals four novel mutations in SERPING1 gene.</article-title>
<source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>2</issue>):<elocation-id>e56712</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0056712</pub-id><?supplied-pmid 23437219?><pub-id pub-id-type="pmid">23437219</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostoni</surname><given-names>A</given-names></name><name><surname>Aygoren-Pursun</surname><given-names>E</given-names></name><name><surname>Binkley</surname><given-names>KE</given-names></name><name><surname>Blanch</surname><given-names>A</given-names></name><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Bouillet</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Hereditary and acquired angioedema: problems and progress: proceedings of the Third C1 Esterase Inhibitor Deficiency Workshop and beyond.</article-title>
<source>J Allergy Clin Immunol</source>. <year>2004</year>;<volume>114</volume>(<issue>3</issue>) <supplement>Suppl</supplement>:<fpage>S51</fpage>&#x02013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2004.06.047</pub-id><?supplied-pmid 15356535?><pub-id pub-id-type="pmid">15356535</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Barnstedt</surname><given-names>SE</given-names></name></person-group>
<article-title>Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema.</article-title>
<source>Arch Intern Med</source>. <year>2001</year>;<volume>161</volume>(<issue>5</issue>):<fpage>714</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1001/archinte.161.5.714</pub-id><?supplied-pmid 11231704?><pub-id pub-id-type="pmid">11231704</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Barnstedt</surname><given-names>SE</given-names></name></person-group>
<article-title>Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema.</article-title>
<source>J Am Dent Assoc</source>. <year>2003</year>;<volume>134</volume>(<issue>8</issue>):<fpage>1088</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.14219/jada.archive.2003.0323</pub-id><?supplied-pmid 12956349?><pub-id pub-id-type="pmid">12956349</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farkas</surname><given-names>H</given-names></name><name><surname>Martinez-Saguer</surname><given-names>I</given-names></name><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Bowen</surname><given-names>T</given-names></name><name><surname>Craig</surname><given-names>T</given-names></name><name><surname>Frank</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency.</article-title>
<source>Allergy</source>. <year>2016</year>;<volume>72</volume>(<issue>2</issue>):<fpage>300</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1111/all.13001</pub-id><?supplied-pmid 27503784?><pub-id pub-id-type="pmid">27503784</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markovi&#x00107;</surname><given-names>AS</given-names></name><name><surname>Rozmanic</surname><given-names>V</given-names></name><name><surname>Anic</surname><given-names>B</given-names></name><name><surname>Aberle</surname><given-names>N</given-names></name><name><surname>Racic</surname><given-names>G</given-names></name><name><surname>Novak</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Guidelines for the diagnosis and treatment of hereditary angioedema.</article-title>
<source>Lijec Vjesn</source>. <year>2014</year>;<volume>136</volume>(<issue>5-6</issue>):<fpage>117</fpage>&#x02013;<lpage>29</lpage>. <comment>[Smjernice za dijagnostiku i lijecenje hereditarnog angioedema]]</comment><?supplied-pmid 25154179?><pub-id pub-id-type="pmid">25154179</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lunn</surname><given-names>ML</given-names></name><name><surname>Santos</surname><given-names>CB</given-names></name><name><surname>Craig</surname><given-names>TJ</given-names></name></person-group>
<article-title>Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients?</article-title>
<source>Ann Allergy Asthma Immunol</source>. <year>2010</year>;<volume>104</volume>(<issue>3</issue>):<fpage>211</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.anai.2009.12.004</pub-id><?supplied-pmid 20377110?><pub-id pub-id-type="pmid">20377110</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sofia</surname><given-names>S</given-names></name><name><surname>Casali</surname><given-names>A</given-names></name><name><surname>Bolondi</surname><given-names>L</given-names></name></person-group>
<article-title>Sonographic findings in abdominal hereditary angioedema.</article-title>
<source>J Clin Ultrasound</source>. <year>1999</year>;<volume>27</volume>(<issue>9</issue>):<fpage>537</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1097-0096(199911/12)27:9&#x0003c;537::AID-JCU9&#x0003e;3.0.CO;2-L</pub-id><?supplied-pmid 10525217?><pub-id pub-id-type="pmid">10525217</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>T</given-names></name><name><surname>Pursun</surname><given-names>EA</given-names></name><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Bowen</surname><given-names>T</given-names></name><name><surname>Boysen</surname><given-names>H</given-names></name><name><surname>Farkas</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>WAO Guideline for the Management of Hereditary Angioedema.</article-title>
<source>Arerugi</source>. <year>2015</year>;<volume>64</volume>(<issue>9</issue>):<fpage>1215</fpage>&#x02013;<lpage>41</lpage>. <comment>[in Japanese]</comment><pub-id pub-id-type="doi">10.15036/arerugi.64.1215</pub-id><?supplied-pmid 26657910?><pub-id pub-id-type="pmid">26657910</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowen</surname><given-names>T</given-names></name><name><surname>Cicardi</surname><given-names>M</given-names></name><name><surname>Farkas</surname><given-names>H</given-names></name><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Longhurst</surname><given-names>HJ</given-names></name><name><surname>Zuraw</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema.</article-title>
<source>Allergy Asthma Clin Immunol</source>. <year>2010</year>;<volume>6</volume>(<issue>1</issue>):<fpage>24</fpage>. <pub-id pub-id-type="doi">10.1186/1710-1492-6-24</pub-id><?supplied-pmid 20667127?><pub-id pub-id-type="pmid">20667127</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aberle</surname><given-names>N</given-names></name><name><surname>Kljaic Bukvic</surname><given-names>B</given-names></name><name><surname>Blekic</surname><given-names>M</given-names></name><name><surname>Vuckovic</surname><given-names>M</given-names></name><name><surname>Bardak</surname><given-names>D</given-names></name><name><surname>Gudelj</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Allergic diseases and atopy among schoolchildren in eastern Croatia.</article-title>
<source>Acta Clin Croat</source>. <year>2018</year>;<volume>57</volume>(<issue>1</issue>):<fpage>82</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.20471/acc.2018.57.01.09</pub-id><?supplied-pmid 30256014?><pub-id pub-id-type="pmid">30256014</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nzeako</surname><given-names>UC</given-names></name><name><surname>Frigas</surname><given-names>E</given-names></name><name><surname>Tremaine</surname><given-names>WJ</given-names></name></person-group>
<article-title>Hereditary angioedema: a broad review for clinicians.</article-title>
<source>Arch Intern Med</source>. <year>2001</year>;<volume>161</volume>(<issue>20</issue>):<fpage>2417</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1001/archinte.161.20.2417</pub-id><?supplied-pmid 11700154?><pub-id pub-id-type="pmid">11700154</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Read</surname><given-names>N</given-names></name><name><surname>Lim</surname><given-names>E</given-names></name><name><surname>Tarzi</surname><given-names>MD</given-names></name><name><surname>Hildick-Smith</surname><given-names>P</given-names></name><name><surname>Burns</surname><given-names>S</given-names></name><name><surname>Fidler</surname><given-names>KJ</given-names></name></person-group>
<article-title>Paediatric hereditary angioedema: a survey of UK service provision and patient experience.</article-title>
<source>Clin Exp Immunol</source>. <year>2014</year>;<volume>178</volume>(<issue>3</issue>):<fpage>483</fpage>&#x02013;<lpage>488</lpage>. <pub-id pub-id-type="doi">10.1111/cei.12433</pub-id><?supplied-pmid 25113655?><pub-id pub-id-type="pmid">25113655</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vukojevi&#x00107;</surname><given-names>M</given-names></name><name><surname>Zovko</surname><given-names>A</given-names></name><name><surname>Talic</surname><given-names>I</given-names></name><name><surname>Tanovic</surname><given-names>M</given-names></name><name><surname>Resic</surname><given-names>B</given-names></name><name><surname>Vrdoljak</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Parental socioeconomic status as a predictor of physical and mental health outcomes in children &#x02013; literature review.</article-title>
<source>Acta Clin Croat</source>. <year>2017</year>;<volume>56</volume>(<issue>4</issue>):<fpage>742</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.20471/acc.2017.56.04.23</pub-id><?supplied-pmid 29590731?><pub-id pub-id-type="pmid">29590731</pub-id></mixed-citation></ref></ref-list></back></article>